BCMA/TACI CAR-T for relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This early-phase study tests a CAR-T cell treatment made to target BCMA and TACI proteins in multiple myeloma. It may help people whose myeloma has come back or did not respond to prior treatments, especially after certain prior therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that is BCMA/TACI positive, or has relapsed after BCMA CAR-T treatment
- Your myeloma has come back after stem cell transplant, or you have returning minimal residual disease (tiny disease signals)
- You have disease outside the bone marrow (extramedullary) that is hard to remove with chemo or radiation, or you meet one of the relapse criteria above
- You are age 18 to 75 and able to do daily activities at a moderate level (ECOG 0 to 2)
- Recent heart, liver, kidney, and oxygen checks are within limits (including heart pumping strength LVEF ≥ 50%)
- You do not have certain brain/heart conditions, serious active infections, HIV, or pregnancy, and you have not had prior CAR-T or other gene-edited T-cell therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
This trial tests a new kind of immunotherapy that uses your own immune cells, called CAR-T cells, to target two specific markers (BCMA and GPRC5D) found on myeloma cells. It's for people whose multiple myeloma has come back or stopped responding to earlier treatments.
This early-phase study tests a lab-made immune treatment (BCMA-targeted CAR-T cells) for people with relapsed or refractory multiple myeloma who have limited options. It may help your body recognize and attack myeloma cells.
This trial tests a one-time BCMA CAR-T cell treatment for people with multiple myeloma that relapsed or did not respond well to prior treatments. It may help by training your own immune cells to recognize and attack myeloma cells.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.